Biogen Inc. (NASDAQ:BIIB) is set to announce second quarter earning results on Wednesday 22nd July 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, BIIB to report 2Q20 income of $ 8.04 per share.
For the full year, analysts anticipate top line of $ 13943.90 million, while looking forward to income of $ 32.96 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 14,000.00 million ~ $ 14,300.00 million, where as bottomline are predicted in a range of $ 31.50 ~ $ 33.50 per share
Click Here For More Historical Outlooks Of Biogen Inc.
Previous Quarter Performance
Biogen Inc. unfold income for the first quarter of $ 9.14 per share, from the revenue of $ 3,534.00 million. The quarterly earnings enlarged 30.95 percent while revenues improved 4.10 percent compared with the same quarter last year.
Street analysts expected Biogen Inc. to report income of $ 7.73 per share on revenue of $ 3406.84 million for the first quarter. The bottom line results beat street analysts by $ 1.41 or 18.24 percent, at the same time, top line results outshined analysts by $ 127.16 million or 3.73 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Biogen Inc.
Stock Performance
According to the previous trading day, closing price of BIIB was $ 280.19, representing a 29.85 % increase from the 52 week low of $ 215.78 and a 25.28 % decrease over the 52 week high of $ 374.99.
The company has a market capital of $ 45.72 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”BIIB” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
On 15th July 2020, maintained by Morgan Stanley at Underweight rating, with $ 263.00 target price.
On 22nd June 2020, downgraded by Barclays to Equal-Weight from Overweight rating, with $ 280.00 target price.
On 22nd June 2020, maintained by RBC Capital at Sector Perform rating, with $ 273.00 target price.
On 19th June 2020, maintained by Robert W. Baird at Underperform rating, with $ 228.00 target price.
On 9th June 2020, downgraded by Bernstein to Market Perform from Outperform rating, with $ 297.00 target price.
Conference Call
Biogen Inc. will be hosting a conference call at 8:00 AM eastern time on 22nd July 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.biogen.com
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.
